Company: NGVT
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001653477-25-000127
Chunk: 51

Company: Ingevity Corp
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 1
Chunk 51
---
(1) Reported net of LIFO Reserve of $7.8 million and $46.3 million for the periods ending September 30, 2025 and December 31, 2024, respectively.The cash flows related to the discontinued operations have not been segregated and are included in the Condensed Consolidated Statements of Cash Flows. The following table presents significant cash flow and non-cash information for the Discontinued Operations:

32

INGEVITY CORPORATIONNotes to the Condensed Consolidated Financial StatementsSeptember 30, 2025(Unaudited)

Nine Months Ended September 30,In millions20252024Cash provided by (used in) operating activities:Adjustments to reconcile net income (loss) to cash provided by (used in) operating activities:Depreciation and amortization$1.1 $8.1 Restructuring and other (income) charges, net33.9 154.5 CTO resales— 50.8 LIFO charge (liquidation)(20.5)3.0 (Gain) loss on strategic investment— 9.3 Goodwill impairment charge— 42.5 CTO supply contract termination charges— 100.0 Changes in operating assets and liabilities, net of effect of acquisitions and divestitures:Restructuring and other cash outflow, net(33.9)(35.6)CTO resales cash inflow (outflow), net6.2 (45.0)CTO supply contract termination cash outflow— (50.0)Cash provided by (used in) investing activities:Capital expenditures$(0.2)$(5.7)

33

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Introduction

Management's discussion and analysis of Ingevity Corporation's ("Ingevity," "the company" "we," "us" or "our") financial condition and results of operations ("MD&A") is provided as a supplement to the Condensed Consolidated Financial Statements and related notes included elsewhere herein to help provide an understanding of our financial condition, changes in financial condition and results of our operations. The following discussion should be read in conjunction with Ingevity's consolidated financial statements as of and for the year ended December 31, 2024, filed on February 19, 2025, with the Securities and Exchange Commission ("SEC") as part of the company's Annual